Disease Overview：Hyperuricemia（HUA）
Hyperuricemia is a metabolic disorder characterized by elevated serum uric acid levels—typically exceeding 6.8 mg/dL—due to either overproduction or underexcretion of uric acid. While often asymptomatic initially, persistent hyperuricemia increases the risk of gouty arthritis, uric acid nephrolithiasis, chronic kidney disease, and cardiovascular comorbidities. Diagnosis relies on fasting serum uric acid measurement, 24-hour urinary uric acid excretion, and imaging (e.g., dual-energy CT) to detect monosodium urate crystal deposition. Management involves lifestyle modification, pharmacologic uricosurics (e.g., probenecid), xanthine oxidase inhibitors (e.g., febuxostat, allopurinol), and, in refractory cases, uricase therapy (e.g., pegloticase). Rheumatology and nephrology specialists collaborate closely to tailor treatment based on renal function, comorbidities, and crystal burden assessment.
China offers distinct advantages for international patients seeking hyperuricemia management. Leading tertiary hospitals—such as Peking Union Medical College Hospital and Shanghai Renji Hospital—house nationally accredited rheumatology centers with extensive experience in complex gout and crystal arthropathy. Advanced diagnostic tools, including DECT and high-resolution ultrasound, enable early crystal detection and treatment response monitoring. Clinical outcomes reflect robust evidence: multi-center studies report >85% sustained uric acid target attainment (<6.0 mg/dL) at 12 months with protocol-driven care. Treatment costs in China are typically 40–60% lower than in the US or Western Europe, without compromising quality—generic and branded urate-lowering agents are widely available and rigorously regulated by the NMPA. As a dedicated medical tourism agency, we facilitate seamless access: coordinating specialist consultations, arranging hospital admissions, providing itemized, transparent pricing in advance, and offering end-to-end support—from visa assistance and accommodation to post-treatment follow-up coordination.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Hyperuricemia (Rheumatology Department)
Non-Surgical / Conservative / Medication Management
*Target Criteria:* Serum uric acid (SUA) ≥420 μmol/L (men) or ≥360 μmol/L (women), with or without gout flares, kidney stones, or chronic kidney disease (CKD) Stage 1–3.
- •Lifestyle Intervention (First-line, mandatory)
- Follow-up visit (30 min, rheumatologist): $28–$42
- •Urate-Lowering Therapy (ULT)
- Baseline labs (SUA, renal function, liver enzymes, CBC): $32 - Monthly SUA monitoring (3 months): $18 × 3 = $54 - Drug cost (30-day supply, 100–300 mg/day): $4–$9 - *Febuxostat (for allopurinol intolerance or CKD Stage 3b+)*: - Baseline labs + HLA-B*5801 genotyping (required in Han Chinese): $32 + $78 = $110 - Monthly SUA monitoring: $54 - Drug cost (30-day supply, 40–80 mg/day): $42–$68 - *Probenecid (only if normal renal function, SUA <540 μmol/L)*: - Baseline labs + 24-hr urine uric acid: $32 + $26 = $58 - Drug cost (30-day supply): $12–$20
Surgical / Procedural / Interventional Options
*Eligibility:* Symptomatic tophaceous gout refractory to ≥6 months of optimized ULT, with functional impairment or infection risk; *no isolated hyperuricemia qualifies for surgery*.
- •Tophus Debridement (Open or Arthroscopic)
- Procedure (single-site, <3 cm tophus): $1,280–$2,150 - Procedure (multi-site or large/complex tophus, e.g., elbow/wrist): $2,450–$4,300 - Post-op pathology + culture: $48
Special / Complex Condition Management
- •Acute Gout Flare in CKD Stage 4–5 (eGFR <30 mL/min):
- Intra-articular corticosteroid injection (ultrasound-guided): $185–$260 - IV corticosteroids (if contraindicated for NSAIDs/colchicine): $110–$155
- •Uric Acid Nephrolithiasis with Obstruction:
- Pre-op CT KUB + metabolic stone panel: $142
Quick Selection Guide
- •Young adult (<45), no comorbidities, SUA 480–520 μmol/L: Start allopurinol + lifestyle ($140 total first 3 months).
- •Elderly (>65), CKD Stage 3a, recurrent flares: Febuxostat + HLA testing ($270 first 3 months); avoid NSAIDs.
- •Budget-constrained patient (<$200 total initial spend): Allopurinol + public hospital lifestyle program ($95 first month).
- •Tophaceous gout with joint deformity: Tophus debridement + immediate febuxostat initiation ($2,800–$5,200 total episode cost).
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Hyperuricemia Medical Vacation Packages
Curated transparent all-inclusive packages combining Hyperuricemia treatment with China top medical destinations:
